Enfusion Inc

Enfusion — Q4 2023 Earnings Presentation

21 slides from Enfusion's earnings presentation, Mar 12, 2024

  1. Slide 1: Enfusion 4Q 2023 Shareholder Letter

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. ©2023 ENFUSION. ALL RIGHTS RESERVED. Enfusion 4Q 2023 Shareholder Letter March 2024

  2. Slide 2: Disclaimer: Forward-Looking Statements

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Disclaimer 2 Forward-Looking Statements Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933 (

  3. Slide 3: Dear Shareholders

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 3 Dear Shareholders, I’m pleased to share that Enfusion ended 2023 with excellent financial performance and increased momentum as we start 2024. Our results demonstrate our ability to navigate a challenging macroeconomic backdrop whil

  4. Slide 4: Our mission

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. To power all investment workflows with our unparalleled technology, relentless innovation, and dedicated focus on clients Our mission 4

  5. Slide 5: We simplify and unify the investment management lifecycle

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. …empowering teams to operate in concert CFO COO CIO Portfolio Manager Analysts Traders Compliance Officer Investor Relations Middle Office Back Office We simplify and unify the investment management lifecycle We manage complex workflo

  6. Slide 6: Serving clients across the investment management industry

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 6 Serving clients across the investment management industry Alternative Investment Managers Hedge Funds Private Equity Private Credit Family Offices Institutional Investment Managers Wealth Managers Traditional Asset Managers Mutual F

  7. Slide 7: Purpose-built end-to-end solution

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Purpose-built end-to-end solution 7 Portfolio Management System Order Execution Management System Technology-Powered Services Accounting / General Ledger Analytics • Live details of portfolio positions • Real-time Investment Book of R

  8. Slide 8: Client-centric approach: Why we win

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 8 Client-centric approach Why we win 4Q23 ARR $185.1 mm One end-to-end solution, one single dataset and source of truth Rapid pace of delivery and evolution Open, flexible and tailored Unique ability to lead with a single solution – a

  9. Slide 9: Q4 2023 key financial highlights

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Q4 2023 key financial highlights $46.5 14.7% YoY Growth Adjusted Free Cash Flow Z00 Total Revenue Z00 Adjusted EBITDA Z00 43.8% FCF Conversion $4.3 $30.9 66.4% Gross Margin Highly attractive SaaS model with combination of scale, growt

  10. Slide 10: Strong growth

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Strong growth $ in millions $40.5 $41.0 $42.7 $44.4 $46.5 4Q22 1Q23 2Q23 3Q23 4Q23 Revenue 10 (1) (1) (1) $(4.1) $27.2 $27.7 $28.5 $29.9 $30.9 $27.5 $27.9 $28.7 $30.2 $31.1 4Q22 1Q23 2Q23 3Q23 4Q23 Gross Profit Adjusted Gross Profit G

  11. Slide 11: Expanding profitability

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Expanding profitability Operating Cash Flow and Adjusted Free Cash Flow $ in millions 11 See appendix for non-GAAP reconciliations. Net Income and Adjusted EBITDA (1) (1) (1) $(4.1) $0.8 $4.7 $1.0 $2.7 $0.9 $6.8 $5.7 $8.0 $8.2 $9.8 4Q

  12. Slide 12: Organic client growth and expansion continues to scale

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. $164.7 $167.0 $171.2 $177.9 $185.1 4Q22 1Q23 2Q23 3Q23 4Q'23 111.5% 106.0% 101.7% 102.4% 102.1% 4Q22 1Q23 2Q23 3Q23 4Q23 Organic client growth and expansion continues to scale 12 Net Dollar Retention Rate (1) Avg Contract Value 819 81

  13. Slide 13: Financial outlook

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Financial outlook 13 These statements are forward-looking and actual results may differ materially. Refer to the “Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results

  14. Slide 14: Appendix

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Appendix

  15. Slide 15: Consolidated Balance Sheets

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 15 ENFUSION, INC. CONSOLIDATED BALANCE SHEETS (dollars and shares in thousands, except par value) (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 35,604 $ 62,545 Accounts receivable, net 28,069 25,855 Prepaid expenses 5

  16. Slide 16: Consolidated Statements of Operations

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 16 ENFUSION, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (dollars and shares in thousands, except per share amounts) (Unaudited) REVENUES: Platformsubscriptions $ 43,054 $ 37,804 $ 161,519 $ 138,868 Managed services 3,056 2,691 11,773

  17. Slide 17: Consolidated Statements of Cash Flows

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 17 ENFUSION, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (dollars in thousands) (Unaudited)

  18. Slide 18: Reconciliations To Non-GAAP Financial Measures

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Reconciliations To Non-GAAP Financial Measures 18 The following table reconciles net income to adjusted EBITDA: The following table reconciles gross profit to adjusted gross profit: ($ in thousands, unaudited) December 31, 2022 March

  19. Slide 19: Reconciliations To Non-GAAP Financial Measures

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Reconciliations To Non-GAAP Financial Measures 19 The following table reconciles operating cash flow to adjusted free cash flow: The Company’s stock-based compensation expense was recognized in the following captions within the consol

  20. Slide 20: Definitions

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 20 Definitions Non-GAAP Financial Measures In addition to financial measures prepared in accordance with GAAP, this presentation and the accompanying tables include Adjusted Diluted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Adjust

  21. Slide 21: Definitions Continued

    PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 21 Definitions Continued Adjusted Net Income and Adjusted Diluted EPS Adjusted Net Income represents net income adjusted to exclude stock-based compensation expense, the effect of foreign currency fluctuations, certain non-recurring i

Enfusion — Q4 2023 Earnings Presentation on 6ix